J&J has joined AbbVie as a partner for Morphic and its small-molecule integrin platform, pledging up to $725 million to the cause.

Cerevel Therapeutics is bringing on Otsuka’s Raymond Sanchez, to serve as chief medical officer and take its CNS assets into phase 3.

Bristol-Myers is testing its leukemia therapy Sprycel in a phase 2 combo study with the anti-PD-1 drug Opdivo in non-small cell lung cancer patients.

The medtech giant has begun rolling out its therapy in the U.S., with the treatment of its first commercially implanted patient.

Robotic surgery giant Intuitive Surgical has received an FDA clearance for its minimally invasive lung cancer biopsy system.

Pluristem has reached a stellar deal with NASA that will see its cell therapies tested against the health problems caused by spending time in space.

The cost-cutting actions come as Vical tries to eke out its cash while looking into strategic alternatives.

Moroney will step down as CEO after his current contract expires in June 2020, or earlier if a successor is appointed before that time.

Novo Nordisk started a new collaboration with Abbott and its Freestyle Libre line of digital health tools and continuous glucose monitoring devices.